Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23 ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...